Hydroxychloroquine for Autoimmune Diseases: How It Works

Hydroxychloroquine tames autoimmune diseases by slipping into the acidic compartments inside immune cells and raising their pH, which disrupts the chain of events that normally triggers inflammation. Originally developed as an antimalarial drug in the mid-twentieth century, it has become one of the most widely prescribed medications in rheumatology, particularly for lupus and rheumatoid arthritis. Its mechanism is unusual compared to most immunosuppressants because it does not broadly shut down the immune system so much as dial down specific overactive pathways, and that subtlety accounts for both its favorable safety profile and the growing list of bonus effects researchers keep discovering.

The pH Trick at the Heart of the Drug

Every cell contains small compartments called lysosomes and endosomes that function a bit like stomachs: they maintain a highly acidic interior to break down proteins, recycle cellular waste, and process foreign material. Hydroxychloroquine is what pharmacologists call a weak base, meaning it preferentially accumulates inside these acidic compartments and neutralizes them, raising the pH closer to neutral.¹ Think of it as pouring baking soda into vinegar: the acid loses its bite. In immune cells, this single chemical change has a cascade of downstream consequences because so many immune functions depend on that acidic environment working correctly.

The drug also interferes with autophagy, the housekeeping process by which cells package and digest their own damaged components. Hydroxychloroquine blocks the fusion of autophagosomes (the packages) with lysosomes (the digestive compartments), causing unprocessed material to pile up inside the cell.² In the context of autoimmune disease, this disruption matters because it slows down the machinery immune cells use to chew up self-proteins and present them as targets for attack.

Shutting Down the Alarm System

When immune cells encounter a suspicious protein fragment, they display it on their surface using molecules called MHC class II. Other immune cells then inspect those fragments, and if they recognize something foreign (or, in autoimmune disease, something that merely looks foreign), they launch an attack. Hydroxychloroquine disrupts this process at its source: by raising the pH of the compartments where proteins are chopped up and loaded onto MHC molecules, it prevents the fragments from binding properly.³ The result is fewer distress signals making it to the cell surface, which means fewer T cells get activated in response.

Animal studies with the closely related drug chloroquine have confirmed that this effect plays out in living organisms, not just in lab dishes. Immune cells from treated animals showed a measurably reduced ability to present certain antigens and stimulate reactive T cells.⁴ This is significant because in diseases like lupus, the immune system’s tendency to treat the body’s own proteins as threats is the root problem. Anything that makes that misidentification harder to pull off reduces disease activity.

Blocking Toll-Like Receptors and Interferon Signals

A second major arm of hydroxychloroquine’s action involves a family of sensors called Toll-like receptors (TLRs), specifically the ones that sit inside endosomes and detect nucleic acids. TLR7 and TLR9, for instance, evolved to detect viral genetic material. In autoimmune disease, they can be tripped by the body’s own DNA and RNA, setting off a false alarm that generates waves of inflammatory signaling molecules called cytokines and type I interferons. Hydroxychloroquine interferes with this signaling by raising the pH of the endosomes where these receptors live.⁵

Research on human dendritic cells has shown that hydroxychloroquine specifically prevents TLR7 from being properly processed into its functional form. The receptor normally needs to be cleaved by enzymes in an acidic environment before it can detect single-stranded RNA. When the drug neutralizes that environment, TLR7 accumulates in its inactive, full-length form and cannot trigger a response.⁶ The practical effect is a drop in type I interferon and inflammatory cytokine production, which dampens the chronic, smoldering inflammation that characterizes diseases like lupus.⁷

This interferon-suppressing action deserves special emphasis because type I interferons are now recognized as central drivers of lupus. Patients with active disease often have a characteristic “interferon signature” in their blood, and several newer biologic drugs target this same pathway at much greater cost. Hydroxychloroquine achieves a partial version of the same effect with a pill that costs very little.

Lupus and the Drug That Changed Outcomes

Systemic lupus erythematosus is the condition most closely associated with hydroxychloroquine, and the evidence here is strong enough that virtually every lupus treatment guideline worldwide recommends the drug for all patients unless they have a specific reason not to take it. Reviews of the clinical evidence have found high-quality support that it prevents lupus flares, improves long-term survival, and offers moderate protection against permanent organ damage, blood clots, and bone loss.⁸

In clinical practice, hydroxychloroquine reduces disease activity scores and allows physicians to lower steroid doses, which is important because long-term steroids come with a heavy side-effect burden of their own. A Japanese study found that these benefits held regardless of whether patients were also taking immunosuppressive drugs, and that flare rates were lower in the hydroxychloroquine group across multiple treatment backgrounds.⁹ The steroid-sparing effect alone is a major practical benefit: it means fewer infections, less bone thinning, and lower diabetes risk over a patient’s lifetime.

What happens when patients stop taking it reinforces the point. A large international cohort study found that reducing or discontinuing hydroxychloroquine substantially raised the risk of flares. Patients who cut their dose had roughly a 20% higher flare risk, while those who stopped entirely had about a 56% higher risk compared to those who stayed on the drug.¹⁰ That finding has made most rheumatologists reluctant to discontinue the drug even when a patient has been in remission for years.

Rheumatoid Arthritis and Triple Therapy

In rheumatoid arthritis, hydroxychloroquine plays a different tactical role. It is rarely used alone for this condition because it is not potent enough by itself to halt joint destruction. Instead, it shows up as part of combination regimens, most famously “triple therapy” alongside methotrexate and sulfasalazine. A landmark trial published in the New England Journal of Medicine found that roughly three-quarters of patients on all three drugs met the response criteria, compared to about a third on methotrexate alone and 40% on the sulfasalazine-hydroxychloroquine pair.¹¹

That triple combination remains a standard option in guidelines today, particularly as a first-line approach before biologic drugs are tried. Hydroxychloroquine appears to enhance the effects of methotrexate specifically, and the combination has the advantage of being inexpensive and widely available.¹² For patients who cannot access or tolerate biologic therapies, triple therapy offers a well-studied alternative with decades of safety data behind it.

Bonus Effects Beyond Immune Suppression

One of the more interesting aspects of hydroxychloroquine is its collection of metabolic and vascular benefits that go beyond what you would expect from a drug primarily prescribed for inflammation. Studies in rheumatoid arthritis patients have found that those taking the drug had significantly lower total cholesterol, LDL cholesterol, and triglycerides, along with higher HDL cholesterol, compared to patients not on the drug.¹³ These differences persisted even after adjusting for whether patients were taking cholesterol-lowering medications, which suggests the effect is independent.

The drug also appears to have antithrombotic properties, meaning it may reduce the risk of blood clots. This is particularly relevant for lupus patients, who already face a heightened clot risk due to the disease itself and to antiphospholipid antibodies that many of them carry. Evidence from both human studies and animal models suggests that hydroxychloroquine reduces thrombosis risk in these patients and may even lower the levels of the problematic antibodies.¹⁴ For a disease that already demands lifelong medication, having one drug that simultaneously addresses inflammation, clot risk, and cholesterol is a considerable practical advantage.

Why It Takes Weeks to Start Working

A common frustration for patients starting hydroxychloroquine is that it can take weeks or even months before noticeable improvement begins. This delay is a direct consequence of the drug’s unusual pharmacokinetics. Hydroxychloroquine has a very large volume of distribution, meaning it spreads extensively into tissues throughout the body rather than staying mostly in the bloodstream. Its half-life is around 40 days, which is extremely long compared to most medications.¹⁵

In practical terms, this means the drug slowly accumulates in tissues over weeks before reaching the concentrations needed to meaningfully alter immune function. The persistence in tissue is not caused by the body being slow to clear it from the blood; instead, the drug distributes so widely into organs, skin, and other tissues that it takes a long time to reach a steady state. The same property also explains why its effects linger for weeks after stopping: the drug leaches back out of tissues gradually. Patients who understand this timeline are less likely to abandon the medication prematurely, which is a genuine problem with hydroxychloroquine adherence.

Protecting the Eyes on Long-Term Use

Retinal toxicity is the most widely discussed safety concern with hydroxychloroquine. The drug can accumulate in the retina over years and cause a form of damage known as hydroxychloroquine retinopathy, which in advanced stages can lead to permanent vision loss.¹⁶ The risk is very low in the first five years of use at standard doses, but it climbs with longer duration and higher cumulative exposure. Current guidelines from the American Academy of Ophthalmology recommend a baseline eye exam within the first year and annual screening starting after five years, using imaging techniques that can detect subtle changes before a patient notices any symptoms.

The tricky part is that early retinopathy is usually asymptomatic. Patients often see perfectly well until the damage has progressed beyond the point where stopping the drug can reverse it. That gap between detectable changes on a scan and symptoms the patient would notice on their own is exactly why screening matters. Most rheumatologists now keep the daily dose at or below 5 mg per kilogram of actual body weight to minimize the risk, a recommendation that has shifted clinical practice toward lower doses than were common a decade ago.

Heart Rhythm and Muscle Concerns

Less common but worth knowing about is the drug’s potential effect on the heart. Hydroxychloroquine can interfere with a specific potassium channel in heart cells called hERG, which helps regulate the heart’s electrical rhythm. Research has shown that the drug promotes degradation of the mature hERG channel protein in a dose- and time-dependent manner, reducing the electrical current the channel carries.¹⁷ Disruption of hERG channels can prolong the QT interval on an electrocardiogram, which in rare cases raises the risk of dangerous heart rhythms.

At the standard doses used in autoimmune disease, clinically significant cardiac toxicity is uncommon. It tends to be reported in patients who have taken the drug for many years, at higher-than-recommended doses, or who have pre-existing heart conditions or kidney disease that slows drug clearance. Some physicians order a baseline electrocardiogram before starting the drug and periodic monitoring in higher-risk patients. Rare cases of cardiomyopathy (weakening of the heart muscle) have also been described, typically resolving or improving after the drug is stopped.

Safety During Pregnancy

Unlike many immunosuppressive drugs, hydroxychloroquine is considered compatible with pregnancy and is actively recommended for pregnant women with lupus. Data from over 300 exposed pregnancies have shown no increased frequency of congenital malformations, and no differences in hearing, vision, or heart rhythm measurements between babies exposed to the drug in utero and those who were not.¹⁸

In fact, the drug appears to offer a specific protective benefit during pregnancy for women who carry anti-SSA/Ro antibodies. These antibodies can cross the placenta and attack the developing baby’s heart conduction system, causing a condition called congenital heart block. Historically, the recurrence rate in subsequent pregnancies after an affected child was about 18%. A prospective study found that hydroxychloroquine reduced this recurrence to about 7.4%, cutting the risk by more than half.¹⁹ Evidence supports its use for preventing recurrence, though data on whether it can prevent a first occurrence (primary prevention) remain limited.²⁰ For women with lupus who are planning a pregnancy, stopping the drug is generally discouraged because of the risk of flares, which themselves threaten the pregnancy.

Blood Level Monitoring

One of the underappreciated problems with hydroxychloroquine therapy is that patients frequently do not take it consistently. The drug’s slow onset makes it easy to skip doses without feeling an immediate consequence, and its side effects (mainly nausea and skin reactions early on) can discourage adherence. Research has found that nonadherence is associated with roughly a threefold higher risk of lupus-related hospitalization.²¹

Measuring hydroxychloroquine blood levels is gaining traction as a way to address this. A blood test can objectively distinguish between a patient who is taking the drug regularly and one who is not, bypassing the unreliability of self-reported adherence. Beyond detecting non-adherence, blood levels can help guide dosing in patients with kidney disease or liver problems that alter how the drug is processed, allowing physicians to tailor therapy at an individual level.²² This approach is not yet universal, but more lupus clinics are adopting it, especially for patients whose disease seems poorly controlled despite being prescribed the drug.

Cutaneous Lupus and Sjögren’s Syndrome

Hydroxychloroquine is also a first-line treatment for cutaneous lupus erythematosus, the form of lupus that primarily affects the skin with rashes, photosensitivity, and scarring lesions. A multicenter randomized trial confirmed its efficacy and tolerability for this indication.²³ Skin-predominant lupus can be particularly disfiguring, and having a well-tolerated oral option that does not require injections or infusions makes hydroxychloroquine the default starting point for most dermatologists managing the condition.

The story is less clear for Sjögren’s syndrome, a condition that attacks moisture-producing glands and causes severe dry eyes and dry mouth. Hydroxychloroquine is widely prescribed for Sjögren’s despite a thin evidence base. A systematic review and meta-analysis concluded that there was not enough high-quality evidence to firmly establish its benefit for the hallmark glandular symptoms, and called for better-designed trials. The review suggested that some extraglandular features like skin involvement or joint pain might respond better, but the data remain inconclusive.²⁴ Many clinicians prescribe it anyway on the basis of its safety profile and the possibility of modest benefit, but patients should know the evidence here is weaker than for lupus or rheumatoid arthritis.

Why the Drug Became Controversial

Hydroxychloroquine spent decades as a quiet workhorse in rheumatology before being thrust into global headlines during the COVID-19 pandemic. Early in vitro studies suggested it might have antiviral activity against SARS-CoV-2, and political endorsements turned it into a cultural flashpoint. Large randomized trials ultimately found no benefit for COVID-19 treatment or prevention, but the episode had real consequences for autoimmune patients: supply shortages left some lupus patients unable to fill their prescriptions, and the drug became so politicized that some patients grew wary of taking it for its actual, well-supported indications.

The pandemic controversy is worth understanding because it highlights a tension in how the drug works. Its ability to raise endosomal pH can theoretically interfere with viral entry and replication in a dish, and the TLR-suppressing effects described earlier could plausibly modulate the overactive immune response seen in severe COVID-19. But “plausible mechanism” and “works in patients” are separated by a wide gulf, and hydroxychloroquine’s story during the pandemic is a case study in why they should not be confused. For autoimmune disease, by contrast, decades of clinical trials have built the evidence base that the COVID-19 trials never could for that indication.